GenSight Biologics expands regulatory leadership in US and Europe
GenSight Biologics appointed Fang Li (Chief Regulatory Affairs & Quality Officer) and Sabrina Chekroun (SVP, Regulatory Affairs and Quality) to strengthen global regulatory strategy for its retinal and central nervous system gene therapy pipeline, citing recent early access program progress and US IND approval as drivers for expanded regulatory engagement.
Why it mattersUS IND approval and new US/France regulatory leads mean teams should prioritize FDA and EMA engagement.